La Jolla Pharmaceutical Company , a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It engages in developing LJPC-501, a formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension; and LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. The company is also developing LJPC-30S, which is the gentamicin derivative program for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.

  • Will La Jolla Continue to Surge Higher?
    on January 27, 2020 at 1:23 pm

    As of late, it has definitely been a great time to be an investor in La Jolla Pharmaceutical.

  • Notable Insider Buys Last Week: Small-Cap Biotechs
    on January 18, 2020 at 10:09 pm

    At two of them, the shares were sold in recent secondary offerings. Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. The following are a few of significant insider purchases reported last week, all small-cap biotechs.

  • Two Small Biotechs See Big Stock Purchases by Their Largest Holders
    on January 15, 2020 at 12:00 pm

    The stocks of La Jolla Pharmaceutical and Milestone Pharmaceuticals have gained this year as investors buy them up.

  • La Jolla Pharmaceutical Company Announces Preliminary GIAPREZA™ (Angiotensin II) Net Sales for the Three and Twelve Months Ended December 31, 2019
    on January 9, 2020 at 1:00 pm

    SAN DIEGO, Jan. 09, 2020 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.

  • Is La Jolla Pharmaceutical Company (LJPC) A Good Stock To Buy?
    on December 13, 2019 at 8:07 pm

    The market has been volatile in the last few months as the Federal Reserve finalized its rate cuts and uncertainty looms over trade negotiations with China. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by more than 10 percentage

  • The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug
    on November 26, 2019 at 1:06 pm

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...

  • La Jolla shares fall on CEO departure, clinical trial results
    on November 25, 2019 at 2:04 pm

    Shares of La Jolla Pharmaceutical Company fell 30% in premarket trading after it announced president and CEO George Tidmarsh had left the company and that the company plans to "re-evaluate its current operating plan" following mixed-results in two clinical studies. La Jolla said it discontinued one study evaluating its experimental treatment, LJPC-401, for iron overload in some patients with beta thalassemia over a lack of efficacy. A separate study testing LJPC-401 as a treatment for patients with hereditary hemochromatosis had met the primary endpoint in a Phase 2 study. La Jolla stock is down 40% year-to-date, while the S&P 500 is up 24%.

  • La Jolla to Reassess Continued Development of LJPC-401 Based on Recent Clinical Results
    on November 25, 2019 at 1:35 pm

    La Jolla Pharmaceutical Company (LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it will reassess continued development of LJPC-401 (synthetic human hepcidin) based on recent mixed clinical results. The Company plans to discontinue Study LJ401-BT01 due to lack of efficacy. The Company recently conducted an interim analysis that included approximately one-half of the target-enrolled patients.

  • La Jolla Pharmaceutical Company Announces Management Transition
    on November 25, 2019 at 1:30 pm

    La Jolla Pharmaceutical Company (LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, has left the Company to pursue other interests. A search for a new Chief Executive Officer has been initiated. In the interim, a committee of the Board, comprised of Kevin Tang and Craig Johnson, will provide Board-level oversight of the Company’s management team.

  • La Jolla Pharmaceutical Company Just Reported And Analysts Have Been Cutting Their Estimates
    on November 15, 2019 at 2:52 pm

    It's been a mediocre week for La Jolla Pharmaceutical Company (NASDAQ:LJPC) shareholders, with the stock dropping 12...

FULL NAME*

What's Your Role?*

WORK EMAIL*

COMPANY NAME*

Company Description*

HOW'D YOU HEAR ABOUT US?

DETAILS ABOUT YOUR GOALS

La Jolla Pharmaceutical Company

10182 Telesis Court
6th Floor
San Diego, CA 92121

+1 (858) 207-4264

www.lajollapharmaceutical.com

January 2020
S M T W T F S
« Nov    
 1234
567891011
12131415161718
19202122232425
262728293031  

©2020 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account